Specification:
Appearance White powder,Colorless clear liquid after reconstitution
Purity ≥95%,by SDS-PAGE(under reducing(R)&Non-reducing conditions,visualized by Coomassie staining)≤10 EU/mg by the LAL method
Endotoxin Determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline
Activity phosphatase production by ATDC-5 chondrogenic cells.The expected ED5o for this effect is 2.0-3.0 ng/ml of Noggin.
Formulation Lyophilized from a 0.22 μm-filtered solution containing PBS,5%mannitol and 0.01%Tween 80,pH 7.4
Size 50 μg/vial,1 mg/vial
Handling and Storage:
Reconstitution It is recommended to redissolve in sterile deionized water.
Shipping The product is shipped with blue ice.
Storage &Stability 36 months at-20℃ to -80℃ in lyophilized state
6months at-20℃ to-80℃ under sterile conditions after reconstitution
7-10 days at 2℃ to 8℃ under sterile conditions after reconstitution
Use a manual defrost freezer and avoid repeated freeze-thaw cycles
Data:
Bioactivity
Measured by its ability to inhibit 5.0 ng/mlof BMP-4 induced alkaline phosphatase production by ATDC-5
chondrocenic cells.The activity of Recombinant Human Noggin (Cat No.Y03301)
is equivalent to
competitor.
产品说明书